cilostazol has been researched along with sirolimus in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC | 1 |
| Cho, EJ; Her, SH; Jang, SW; Kim, DB; Kim, JH; Kwon, BJ; Park, CS; Park, HJ; Park, MW; Rho, TH; Shin, D | 1 |
| Akishita, M; Ako, J; Eto, M; Iijima, K; Ogawa, S; Ota, H; Ouchi, Y | 1 |
| Furukawa, Y; Kadota, K; Kimura, T; Kita, T; Mitsudo, K; Morimoto, T; Nakagawa, Y; Nakao, T; Nobuyoshi, M | 1 |
| Ahn, SG; Choi, H; Hong, MK; Hong, YJ; Jang, Y; Kwon, HM; Lee, JW; Lee, SH; Yoon, J; Youn, YJ; Yu, CW | 1 |
| Byrne, RA; Guerra, E; Kastrati, A | 1 |
| Chang, K; Choi, YS; Chung, WB; Chung, WS; Kim, HY; Kim, JY; Kwon, A; Lee, MY; Park, CS; Seung, KB | 1 |
| Abizaid, A; Costa, JR; Costa, R; Feres, F; Mangione, JA; Piva E Mattos, LA; Siqueira, D; Sousa, A; Staico, R; Zuliani Mauro, MF | 1 |
| Bae, JH; Bae, JW; Chae, IH; Cho, MC; Cho, YS; Choi, DJ; Kang, HJ; Kim, HS; Koo, BK; Kwon, TG; Lee, SP; Park, K; Rha, SW; Suh, JW; Youn, TJ | 1 |
| Li, J; Xiang, X; Xu, Z | 1 |
| Adeva-Andany, MM; Carneiro-Freire, N; Castro-Quintela, E; Fernández-Fernández, C; González-Lucán, M; Vila-Altesor, M | 1 |
2 review(s) available for cilostazol and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological inhibition of coronary restenosis: systemic and local approaches.
Topics: Anti-Bacterial Agents; Antioxidants; Cilostazol; Coronary Restenosis; Drug Delivery Systems; Drug-Eluting Stents; Humans; ortho-Aminobenzoates; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Probucol; Sirolimus; Tetrazoles; Tubulin Modulators; Vasodilator Agents | 2014 |
4 trial(s) available for cilostazol and sirolimus
| Article | Year |
|---|---|
Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug Delivery Systems; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Tunica Intima | 2007 |
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
Topics: Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Tetrazoles; Ticlopidine; Treatment Outcome | 2017 |
The Effect of Cilostazol on the Angiographic Outcome of Drug-Eluting Coronary Stents Angiographic Analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial.
Topics: Aged; Antineoplastic Agents; Cilostazol; Coronary Angiography; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Tetrazoles | 2017 |
6 other study(ies) available for cilostazol and sirolimus
| Article | Year |
|---|---|
Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occlusion; Coronary Stenosis; Coronary Thrombosis; Drug-Eluting Stents; Electrocardiography; Fatal Outcome; Humans; Immunosuppressive Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Sirolimus; Tetrazoles; Ticlopidine; Ventricular Fibrillation | 2010 |
Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.
Topics: Aspirin; Cellular Senescence; Cilostazol; Clopidogrel; Down-Regulation; Drug-Eluting Stents; Endothelium, Vascular; Everolimus; Humans; Immunosuppressive Agents; Nitric Oxide Synthase Type III; Oxidative Stress; Paclitaxel; Plasminogen Activator Inhibitor 1; Platelet Aggregation Inhibitors; Sirolimus; Sirtuin 1; Sirtuins; Tetrazoles; Ticlopidine; Vasodilator Agents | 2009 |
The long-term efficacy of cilostazol in addition to dual antiplatelet therapy after sirolimus-eluting stent implantation for Japanese patients: an analysis of the 3-year follow-up outcomes from the j-Cypher registry.
Topics: Aged; Aged, 80 and over; Asian People; Cilostazol; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Sirolimus; Survival Rate; Tetrazoles; Treatment Outcome | 2012 |
It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Registries; Sirolimus; Tetrazoles; Thrombosis; Ticlopidine; Treatment Outcome | 2015 |
Cilostazol protects against myocardial ischemia and reperfusion injury by activating transcription factor EB (TFEB).
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cilostazol; Disease Models, Animal; Lysosomes; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley; Sirolimus | 2019 |
Cardiovascular Protection Associated With Cilostazol, Colchicine, and Target of Rapamycin Inhibitors.
Topics: Cilostazol; Colchicine; Coronary Artery Disease; Cyclic AMP; Diabetes Mellitus, Type 2; Humans; Muscle, Smooth, Vascular; Sirolimus; Tetrazoles; Vascular Diseases | 2022 |